Related Experiment Videos

[Components of the classical complement pathway in systemic lupus erythematosus]

Presse Medicale (Paris, France : 1983)
|March 7, 1987
PubMed

Insights

Genetic deficiencies in complement component 4 (C4) are linked to low levels of CH50, C4, and C2 in systemic lupus erythematosus (SLE) patients. These deficiencies, whether isolated or with complement activation, do not reliably indicate disease activity.

Area of Science:

  • Immunology
  • Genetics
  • Rheumatology

Context:

  • Systemic lupus erythematosus (SLE) is an autoimmune disease.
  • Complement system components, including C4 and C2, play a role in immune responses.
  • Genetic variations in complement genes can influence disease susceptibility and presentation.

Purpose:

  • To investigate the relationship between decreased complement component levels (CH50, C4, C2) and genetic factors in SLE patients and their relatives.
  • To determine if C4 deficiency is associated with complement activation in SLE.
  • To assess the utility of measuring C4 and C2 levels for monitoring SLE disease activity.

Summary:

  • Decreased levels of CH50, C4, and C2 in SLE patients and relatives are often associated with genetic deficiencies in the C4 gene loci.
  • C4 deficiency can occur in isolation or be linked to complement activation, detectable via C3a des Arg levels in some cases.
  • Reduced C4 and C2 concentrations or hemolytic activity in SLE do not serve as reliable indicators of disease activity.

Impact:

  • Identifies genetic C4 deficiency as a primary cause for reduced C4 and C2 levels in a subset of SLE patients.
  • Highlights the complex interplay between genetic complement deficiencies and complement system activation in SLE.
  • Clarifies that C4 and C2 levels are not suitable biomarkers for assessing SLE disease activity, guiding future research and clinical practice.

Related Concept Videos